This is Lever Weekly, a recap of our work from the past week. If you only read one email from us all week, this should be it.

What The Lever Published This Week: 

Trump’s Tech Donors Have Big Plans For Greenland
A Trump takeover of Greenland could open the door to tech moguls’ mineral interests and their utopian aspirations.
Trump’s AI Moonshot Leads To Saudi Arabia
Trump’s economic projects involve billions from the Saudi Arabian government — and the committee overseeing the deals is stacked with Saudi-connected officials.
Trump’s EPA Just Deleted Climate Change
The environmental agency just scrubbed most mentions of the global crisis from its online presence.
The Hidden Cost Behind Your “$0 Copay” Drug Assistance Program
Copay assistance programs are supposed to reduce drug costs and cover patients’ deductibles — so why are so many people getting stuck with a bill?
The American Dream (Water Not Included)
Real estate developers are running a dark-money campaign to overturn new housing rules — and ignore basic laws of nature.
From Watergate to Elon-gate
Musk is trying to shut down the agency probing his company’s equipment — and now workers are pushing back with a longstanding privacy law.
Trump’s Mar-a-Gaza Dream
Who is behind Trump’s plan to “take over the Gaza Strip” and turn it into the “Riviera of the Middle East”?
Bondi’s License To Shill
The lobbyist-turned-AG just limited enforcement of anti-corruption laws regulating foreign agents trying to influence U.S. officials.
YOU LOVE TO SEE IT: Whale Of A Win
Right whales get their rights back, abortion providers are handed a shield, Trump has an antitrust moment, and a tractor company is told to repair its values.

The Lever In The News:

  • Gizmodo — The tech-focused website featured our reporting on the mining startup that may secretly be behind Trump’s wild push for Greenland.
  • Gizmodo — The website also featured our reporting on Elon Musk’s potential motives for destroying the government’s international humanitarian agency.
  • Sunday Long Read — The popular newsletter, which compiles the week’s best features, included our reporting on controversial new Alzheimer’s drugs.